

Sarosh Rana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5185733/publications.pdf>

Version: 2024-02-01

106
papers

6,016
citations

117625

34
h-index

76900

74
g-index

108
all docs

108
docs citations

108
times ranked

5222
citing authors

#	ARTICLE	IF	CITATIONS
1	Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. American Journal of Obstetrics and Gynecology, 2022, 226, S1019-S1034.	1.3	120
2	The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertension, 2022, 27, 148-169.	1.4	189
3	Prevalence and management of severe intrapartum hypertension in patients with preeclampsia at an urban tertiary care medical center. Pregnancy Hypertension, 2022, 27, 87-93.	1.4	1
4	Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertension, 2022, 27, 42-50.	1.4	55
5	Angiogenesis and Preeclampsia. , 2022, , 165-185.		0
6	Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. Clinical Chemistry, 2022, 68, 771-781.	3.2	8
7	Elimination of racial disparities in postpartum hypertension follow-up after incorporation of telehealth into a quality bundle. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100580.	2.6	17
8	Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement From the American Heart Association. Hypertension, 2022, 79, HYP0000000000000208.	2.7	161
9	Racial Disparities in Diagnosis, Management, and Outcomes in Preeclampsia. Current Hypertension Reports, 2022, 24, 87-93.	3.5	8
10	Racial Differences in Readmissions in Hypertensive Disorders of Pregnancy. Reproductive Sciences, 2022, 29, 2071-2078.	2.5	3
11	Women's perspectives and attitudes towards the utility of angiogenic biomarkers in preeclampsia. Pregnancy Hypertension, 2022, 28, 109-113.	1.4	0
12	Maternal mortality in the United States: The pervasive effects of racism. Med, 2022, 3, 361-364.	4.4	0
13	Luteolin-induced vasorelaxation in uterine arteries from normal pregnant rats. Pregnancy Hypertension, 2021, 23, 11-17.	1.4	8
14	Real-World Use of Biomarkers in Management of Hypertension During Pregnancy. Hypertension, 2021, 77, 472-474.	2.7	2
15	Long-Term Postpartum Cardiac Function and Its Association With Preeclampsia. Journal of the American Heart Association, 2021, 10, e018526.	3.7	25
16	Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource Setting: ROBUST study. Pregnancy Hypertension, 2021, 23, 97-103.	1.4	9
17	Treat It While You Can. Hypertension, 2021, 77, 1525-1527.	2.7	2
18	Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy. Circulation, 2021, 143, 1852-1862.	1.6	65

#	ARTICLE	IF	CITATIONS
19	Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction. American Journal of Obstetrics & Gynecology MFM, 2021, 3, 100394.	2.6	5
20	Angiogenic factors and prediction for ischemic placental disease in future pregnancies. Pregnancy Hypertension, 2021, 25, 12-17.	1.4	5
21	The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center. Pregnancy Hypertension, 2021, 25, 7-11.	1.4	1
22	Long-Term Cardiovascular Disease Risk in Women After Hypertensive Disorders of Pregnancy: Recent Advances in Hypertension. Hypertension, 2021, 78, 927-935.	2.7	40
23	Postpartum Outcomes With Systematic Treatment and Management of Postpartum Hypertension. Obstetrics and Gynecology, 2021, 138, 777-787.	2.4	20
24	Is Prolonging Gestation in Preeclampsia For Better or Worse in Preventing Cardiovascular Disease?. Hypertension, 2021, 78, 1395-1397.	2.7	0
25	Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States. Pregnancy Hypertension, 2021, 26, 121-126.	1.4	3
26	Severe antepartum hypertension and associated peripartum morbidity among pregnant women in an urban tertiary care medical center. Pregnancy Hypertension, 2020, 19, 31-36.	1.4	4
27	Derivation of endometrial gland organoids from term placenta. Placenta, 2020, 101, 75-79.	1.5	21
28	Transcriptome and regulatory maps of decidua-derived stromal cells inform gene discovery in preterm birth. Science Advances, 2020, 6, .	10.3	31
29	Evaluation of angiogenic factors in the decision to admit women with suspected preeclampsia. Pregnancy Hypertension, 2020, 21, 124-131.	1.4	8
30	Antepartum Aspirin Administration Reduces Activin A and Cardiac Global Longitudinal Strain in Preeclamptic Women. Journal of the American Heart Association, 2020, 9, e015997.	3.7	11
31	Effect of blood pressure control in early pregnancy and clinical outcomes in African American women with chronic hypertension. Pregnancy Hypertension, 2020, 20, 102-107.	1.4	5
32	Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension. Pregnancy Hypertension, 2020, 20, 124-130.	1.4	13
33	798: IMPACT OF HYPERTENSIVE DISEASE OF PREGNANCY ON RISK OF RECURRENT READMISSIONS DUE TO HEART FAILURE. Critical Care Medicine, 2020, 48, 379-379.	0.9	0
34	Validation of Soluble Fms-Like Tyrosine Kinase-1 (sFlt-1) and Placental Growth Factor (PlGF) Assays on Cobas e602 System. American Journal of Clinical Pathology, 2020, 154, S12-S13.	0.7	0
35	THE GRAVID ATRIUM: AN UNCOMMON CAUSE OF SHORTNESS OF BREATH IN PREGNANCY AND THE EXPANDING ROLE OF CARDIAC MAGNETIC RESONANCE IMAGING IN THE EVALUATION OF CARDIAC MASSES. Journal of the American College of Cardiology, 2019, 73, 2259.	2.8	0
36	Understanding and comparing practices of managing patients with hypertensive disorders of pregnancy in urban China and the United States. Pregnancy Hypertension, 2019, 17, 253-260.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Luteolin protect hGEncs from TNF- α -induced endothelial dysfunction by attenuating ET-1 and ROS production. <i>Pregnancy Hypertension</i> , 2019, 17, S24-S25.	1.4	0
38	Preeclampsia. <i>Circulation Research</i> , 2019, 124, 1094-1112.	4.5	1,019
39	Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients. <i>Hypertension</i> , 2019, 73, 868-877.	2.7	36
40	Risk Factors of Subsequent Preeclampsia in Multiparous Women Among a Primarily African American Cohort [26P]. <i>Obstetrics and Gynecology</i> , 2019, 133, 177S-177S.	2.4	0
41	Hypertensive Diseases of Pregnancy Increase Risk of Readmission With Heart Failure: A National Readmissions Database Study. <i>Mayo Clinic Proceedings</i> , 2019, 94, 811-819.	3.0	10
42	Luteolin protects human glomerular endothelial cells from TNF- α -induced endothelial dysfunction by attenuating ET-1 and ROS production. <i>FASEB Journal</i> , 2019, 33, 865.9.	0.5	0
43	Household air pollution and chronic hypoxia in the placenta of pregnant Nigerian women: A randomized controlled ethanol Cookstove intervention. <i>Science of the Total Environment</i> , 2018, 619-620, 212-220.	8.0	25
44	Analytical validation of soluble fms-like tyrosine and placental growth factor assays on BIA-CRIS KRYPTOR Compact Plus automated immunoassay platform. <i>Pregnancy Hypertension</i> , 2018, 11, 66-70.	1.4	11
45	Association of Levels of Antepartum Angiogenic Factors with Severe Postpartum Hypertension [25I]. <i>Obstetrics and Gynecology</i> , 2018, 131, 104S-104S.	2.4	0
46	Association of antepartum blood pressure levels and angiogenic profile among women with chronic hypertension. <i>Pregnancy Hypertension</i> , 2018, 14, 110-114.	1.4	9
47	Activin A and Late Postpartum Cardiac Dysfunction Among Women With Hypertensive Disorders of Pregnancy. <i>Hypertension</i> , 2018, 72, 188-193.	2.7	33
48	Angiogenic biomarkers in triage and risk for preeclampsia with severe features. <i>Pregnancy Hypertension</i> , 2018, 13, 100-106.	1.4	43
49	Myocardial performance index in hypertensive disorders of pregnancy: The relationship between blood pressures and angiogenic factors. <i>Hypertension in Pregnancy</i> , 2017, 36, 161-167.	1.1	13
50	Angiogenic Proteins. <i>Hypertension</i> , 2017, 69, 401-403.	2.7	3
51	Household air pollution and angiogenic factors in pregnant Nigerian women: A randomized controlled ethanol cookstove intervention. <i>Science of the Total Environment</i> , 2017, 599-600, 2175-2181.	8.0	14
52	Abnormal mid-trimester cardiac strain in women with chronic hypertension predates superimposed preeclampsia. <i>Pregnancy Hypertension</i> , 2017, 10, 251-255.	1.4	18
53	Increased Perinatal Morbidity and Mortality Among Asian American and Pacific Islander Women in the United States. <i>Anesthesia and Analgesia</i> , 2017, 124, 879-886.	2.2	16
54	Prevalence, risk factors and associated complications of postpartum hypertension in rural Haiti. <i>Pregnancy Hypertension</i> , 2017, 10, 135-142.	1.4	9

#	ARTICLE	IF	CITATIONS
55	Outcomes and mortality in parturient and non-parturient patients with peripartum cardiomyopathy: A national readmission database study. <i>Pregnancy Hypertension</i> , 2017, 10, 143-148.	1.4	5
56	Cardiogenic shock in pregnancy: Analysis from the National Inpatient Sample. <i>Hypertension in Pregnancy</i> , 2017, 36, 117-123.	1.1	38
57	KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. <i>Hypertension in Pregnancy</i> , 2016, 35, 330-345.	1.1	34
58	Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. <i>Hypertension</i> , 2016, 67, 1273-1280.	2.7	57
59	Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy. <i>Pregnancy Hypertension</i> , 2016, 6, 333-339.	1.4	9
60	Sequential plasma angiogenic factors levels in women with suspected preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 89.e1-89.e10.	1.3	56
61	Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy. <i>JACC: Heart Failure</i> , 2016, 4, 380-388.	4.1	68
62	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 214, 108.e1-108.e14.	1.3	122
63	Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. <i>PLoS ONE</i> , 2015, 10, e0126815.	2.5	48
64	Racial Disparities in Comorbidities, Complications, and Maternal and Fetal Outcomes in Women With Preeclampsia/eclampsia. <i>Hypertension in Pregnancy</i> , 2015, 34, 506-515.	1.1	110
65	Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. <i>Prenatal Diagnosis</i> , 2015, 35, 386-393.	2.3	28
66	Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. <i>Circulation</i> , 2015, 132, 1726-1733.	1.6	111
67	Maternal risk factors for neonatal necrotizing enterocolitis. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015, 28, 1285-1290.	1.5	20
68	Ouabain inhibits placental sFlt1 production by repressing HSP27-dependent HIF1 α pathway. <i>FASEB Journal</i> , 2014, 28, 4324-4334.	0.5	47
69	Response to Carbillon L et al. letter titled; "The imbalance of circulating angiogenic/anti-angiogenic factors is mild or absent in obese women destined to develop preeclampsia". <i>Hypertension in Pregnancy</i> , 2014, 33, 525-525.	1.1	1
70	Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. <i>Hypertension in Pregnancy</i> , 2014, 33, 427-439.	1.1	38
71	Adverse maternal and fetal outcomes and deaths related to preeclampsia and eclampsia in Haiti. <i>Pregnancy Hypertension</i> , 2014, 4, 279-286.	1.4	23
72	Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. <i>Hypertension in Pregnancy</i> , 2014, 33, 250-259.	1.1	36

#	ARTICLE	IF	CITATIONS
73	The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. <i>Hypertension in Pregnancy</i> , 2014, 33, 81-92.	1.1	45
74	Angiogenic Factors in Diagnosis, Management, and Research in Preeclampsia. <i>Hypertension</i> , 2014, 63, 198-202.	2.7	106
75	Angiogenic factors in preeclampsia. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, 643-650.	2.0	27
76	The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. <i>Journal of Perinatal Medicine</i> , 2013, 41, 511-516.	1.4	64
77	Circulating Lymphangiogenic Factors in Preeclampsia. <i>Hypertension in Pregnancy</i> , 2013, 32, 42-49.	1.1	17
78	Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. <i>Hypertension in Pregnancy</i> , 2013, 32, 189-201.	1.1	130
79	Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 1135-1141.	1.5	17
80	Management of abnormal serum markers in the absence of aneuploidy or neural tube defects. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 1895-1898.	1.5	1
81	Transcriptionally Active Syncytial Aggregates in the Maternal Circulation May Contribute to Circulating Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia. <i>Hypertension</i> , 2012, 59, 256-264.	2.7	148
82	Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia. <i>Circulation</i> , 2012, 125, 911-919.	1.6	526
83	Circulating Angiogenic Factors and Risk of Adverse Maternal and Perinatal Outcomes in Twin Pregnancies With Suspected Preeclampsia. <i>Hypertension</i> , 2012, 60, 451-458.	2.7	84
84	Angiogenic Factors and Pregnant Woman with New Onset Seizures. <i>Hypertension in Pregnancy</i> , 2012, 31, 207-210.	1.1	2
85	Subclinical Left Ventricular Dysfunction in Preeclamptic Women With Preserved Left Ventricular Ejection Fraction. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 734-739.	2.6	100
86	Physicians' Knowledge of Future Vascular Disease in Women with Preeclampsia. <i>Hypertension in Pregnancy</i> , 2012, 31, 50-58.	1.1	93
87	Placental Origins of Angiogenic Dysfunction in Mirror Syndrome. <i>Hypertension in Pregnancy</i> , 2012, 31, 211-217.	1.1	15
88	Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. <i>Nature</i> , 2012, 485, 333-338.	27.8	450
89	Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in Patients with Suspected Preeclampsia. <i>PLoS ONE</i> , 2012, 7, e48259.	2.5	49
90	Rupture of the Posterior Cul-De-Sac During Spontaneous Labor. <i>Obstetrics and Gynecology</i> , 2010, 115, 414-417.	2.4	11

#	ARTICLE	IF	CITATIONS
91	First Trimester Vitamin D, Vitamin D Binding Protein, and Subsequent Preeclampsia. <i>Hypertension</i> , 2010, 56, 758-763.	2.7	151
92	The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010, 23, 366-370.	1.5	50
93	The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2010, 23, 1-6.	1.5	26
94	Preeclampsia: The Role of Angiogenic Factors in Its Pathogenesis. <i>Physiology</i> , 2009, 24, 147-158.	3.1	384
95	Risk for developing gestational diabetes in women with twin pregnancies. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2009, 22, 293-299.	1.5	120
96	Use of Circulating Antiangiogenic Factors to Differentiate Other Hypertensive Disorders From Preeclampsia in a Pregnant Woman on Dialysis. <i>American Journal of Kidney Diseases</i> , 2008, 51, 1029-1032.	1.9	25
97	Angiogenic proteins as markers for predicting preeclampsia. <i>Expert Review of Obstetrics and Gynecology</i> , 2007, 2, 61-65.	0.4	6
98	Sequential Changes in Antiangiogenic Factors in Early Pregnancy and Risk of Developing Preeclampsia. <i>Hypertension</i> , 2007, 50, 137-142.	2.7	271
99	Circulating Levels of the Antiangiogenic Marker Soluble FMS-Like Tyrosine Kinase 1 Are Elevated in Women With Pregestational Diabetes and Preeclampsia: Angiogenic markers in preeclampsia and preexisting diabetes. <i>Diabetes Care</i> , 2007, 30, 375-377.	8.6	23
100	Cytomegalovirus-Induced Mirror Syndrome Associated With Elevated Levels of Circulating Antiangiogenic Factors. <i>Obstetrics and Gynecology</i> , 2007, 109, 549-552.	2.4	58
101	Cytomegalovirus-Induced Mirror Syndrome Associated With Elevated Levels of Angiogenic Factors. <i>Obstetrics and Gynecology</i> , 2007, 109, 1206.	2.4	0
102	Neuropsychological performance in normal pregnancy and preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 186-191.	1.3	17
103	Fetal cheek-to-cheek diameter in the prediction of mode of delivery. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 192, 1205-1211.	1.3	17
104	Stage IIIC Small Cell Carcinoma of the Ovary: Survival With Conservative Surgery and Chemotherapy. <i>Obstetrics and Gynecology</i> , 2004, 103, 1120-1123.	2.4	26
105	Retroperitoneal Endometriosis Causing Unilateral Hip Pain. <i>Obstetrics and Gynecology</i> , 2001, 98, 970-972.	2.4	3
106	Ransom SB, Dombrowski MP, McNeeley SG, Moghissi KS, Munkarah AR, eds. <i>Practical Strategies in Obstetrics and Gynecology</i> . 1st ed. Philadelphia: W.B. Saunders, 2000.. <i>Fertility and Sterility</i> , 2000, 74, 425.	1.0	0